High sensitivity, increased specificity, and
improved precision
for accurate
prediction of recurrence and
better stratification
patients with
improved PFS over genomic-only
methods1,2
Enhanced Performance
Rapid Turnaround Time
Averaging 9 days in the
clinical setting to
accelerate
trial
enrollment and assess
response sooner3,4
MRD, minimal residual disease; PFS, progression-free survival.
QUANTIFY CANCER
Guardant Infinity enables liquid-only MRD and response monitoring that is accessible and scalable across clinical trials.
Tissue-Free Sampling
A simple blood draw
making it significantly
easier to
acquire, enabling
a higher evaluable rate for
clinical studies
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma